Scientists have shown how thalidomide analogs mediate degradation of many more proteins than previously anticipated. These proteins -- zinc finger transcription factors -- play a role in cancer and developmental diseases but are difficult drug targets. The new study suggests that thalidomide analogs can be rationally designed to target this challenging class of proteins.